Opinion|Videos|August 22, 2024
EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly share perspective/insights on emerging novel agents in R/R CLL: BTKi degraders
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
4
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
5